Literature DB >> 16004919

Pulmonary disorders in the training room.

James S Pope1, Steven M Koenig.   

Abstract

For the athlete, not only can pulmonary disorders cause significant alterations in training schedules or even prolonged stoppages, they can be life-threatening. Infectious diseases such as acute bronchitis, influenza, and pneumonia conspire to disrupt exercise regimens. Pneumothorax, vocal cord dysfunction, and exercise-induced asthma may present diagnostic and treatment challenges. Obstructive sleep apnea not only causes disruptive symptoms but can be associated with significant cardiovascular morbidity and even mortality. This article addresses the most common pulmonary conditions athletes face and provides a framework for the diagnosis and treatment of these conditions.

Entities:  

Mesh:

Year:  2005        PMID: 16004919     DOI: 10.1016/j.csm.2005.05.003

Source DB:  PubMed          Journal:  Clin Sports Med        ISSN: 0278-5919            Impact factor:   2.182


  5 in total

Review 1.  Use of prescription drugs in athletes.

Authors:  Antti Alaranta; Hannu Alaranta; Ilkka Helenius
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

Review 2.  Cough in the Athlete: CHEST Guideline and Expert Panel Report.

Authors:  Louis-Philippe Boulet; Julie Turmel; Richard S Irwin
Journal:  Chest       Date:  2016-11-16       Impact factor: 9.410

Review 3.  Pulmonary and cardiac infections in athletes.

Authors:  Roger J Kruse; Cathy L Cantor
Journal:  Clin Sports Med       Date:  2007-07       Impact factor: 2.182

4.  Infection Risk Reduction Program on Pathogens in High School and Collegiate Athletic Training Rooms.

Authors:  Mark W LaBelle; Derrick M Knapik; James W Arbogast; Steve Zhou; Lisa Bowersock; Albert Parker; James E Voos
Journal:  Sports Health       Date:  2019-10-29       Impact factor: 3.843

Review 5.  Lower respiratory infections and potential complications in athletes.

Authors:  Todd M Lorenc; Michael T Kernan
Journal:  Curr Sports Med Rep       Date:  2006-04       Impact factor: 1.733

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.